• Something wrong with this record ?

Identification of new anti-mycobacterial agents based on quinoline-isatin hybrids targeting enoyl acyl carrier protein reductase (InhA)

EF. Khaleel, A. Sabt, M. Korycka-Machala, RM. Badi, NT. Son, NX. Ha, MF. Hamissa, AE. Elsawi, EB. Elkaeed, B. Dziadek, WM. Eldehna, J. Dziadek

. 2024 ; 144 (-) : 107138. [pub] 20240120

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24006904

Tuberculosis (TB) is a global issue that poses a significant economic burden as a result of the ongoing emergence of drug-resistant strains. The urgent requirement for the development of novel antitubercular drugs can be addressed by targeting specific enzymes. One such enzyme, Mycobacterium tuberculosis (MTB) enoyl-acyl carrier protein (enoyl-ACP) reductase (InhA), plays a crucial role in the survival of the MTB bacterium. In this research study, a series of hybrid compounds combining quinolone and isatin were synthesized and assessed for their effectiveness against MTB, as well as their ability to inhibit the activity of the InhA enzyme in this bacterium. Among the compounds tested, 7a and 5g exhibited the most potent inhibitory activity against MTB, with minimum inhibitory concentration (MIC) values of 55 and 62.5 μg/mL, respectively. These compounds were further evaluated for their inhibitory effects on InhA and demonstrated significant activity compared to the reference drug Isoniazid (INH), with IC50 values of 0.35 ± 0.01 and 1.56 ± 0.06 μM, respectively. Molecular docking studies investigated the interactions between compounds 7a and 5g and the target enzyme, revealing hydrophobic contacts with important amino acid residues in the active site. To further confirm the stability of the complexes formed by 5g and 7a with the target enzyme, molecular dynamic simulations were employed, which demonstrated that both compounds 7a and 5g undergo minor structural changes and remain nearly stable throughout the simulated process, as assessed through RMSD, RMSF, and Rg values.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006904
003      
CZ-PrNML
005      
20240423155550.0
007      
ta
008      
240412e20240120xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bioorg.2024.107138 $2 doi
035    __
$a (PubMed)38262087
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Khaleel, Eman F $u Department of Medical Physiology, College of Medicine, King Khalid University, Asir 61421, Saudi Arabia
245    10
$a Identification of new anti-mycobacterial agents based on quinoline-isatin hybrids targeting enoyl acyl carrier protein reductase (InhA) / $c EF. Khaleel, A. Sabt, M. Korycka-Machala, RM. Badi, NT. Son, NX. Ha, MF. Hamissa, AE. Elsawi, EB. Elkaeed, B. Dziadek, WM. Eldehna, J. Dziadek
520    9_
$a Tuberculosis (TB) is a global issue that poses a significant economic burden as a result of the ongoing emergence of drug-resistant strains. The urgent requirement for the development of novel antitubercular drugs can be addressed by targeting specific enzymes. One such enzyme, Mycobacterium tuberculosis (MTB) enoyl-acyl carrier protein (enoyl-ACP) reductase (InhA), plays a crucial role in the survival of the MTB bacterium. In this research study, a series of hybrid compounds combining quinolone and isatin were synthesized and assessed for their effectiveness against MTB, as well as their ability to inhibit the activity of the InhA enzyme in this bacterium. Among the compounds tested, 7a and 5g exhibited the most potent inhibitory activity against MTB, with minimum inhibitory concentration (MIC) values of 55 and 62.5 μg/mL, respectively. These compounds were further evaluated for their inhibitory effects on InhA and demonstrated significant activity compared to the reference drug Isoniazid (INH), with IC50 values of 0.35 ± 0.01 and 1.56 ± 0.06 μM, respectively. Molecular docking studies investigated the interactions between compounds 7a and 5g and the target enzyme, revealing hydrophobic contacts with important amino acid residues in the active site. To further confirm the stability of the complexes formed by 5g and 7a with the target enzyme, molecular dynamic simulations were employed, which demonstrated that both compounds 7a and 5g undergo minor structural changes and remain nearly stable throughout the simulated process, as assessed through RMSD, RMSF, and Rg values.
650    _2
$a lidé $7 D006801
650    _2
$a protein přenášející acyl $x farmakologie $7 D000213
650    12
$a isatin $x farmakologie $7 D007510
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a oxidoreduktasy $x metabolismus $7 D010088
650    _2
$a antituberkulotika $x farmakologie $x chemie $7 D000995
650    12
$a Mycobacterium tuberculosis $7 D009169
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    12
$a chinoliny $x farmakologie $7 D011804
650    _2
$a bakteriální proteiny $x metabolismus $7 D001426
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sabt, Ahmed $u Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Center, Dokki, Cairo 12622, Egypt
700    1_
$a Korycka-Machala, Malgorzata $u Laboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology of the Polish Academy of Sciences, Lodz, Poland
700    1_
$a Badi, Rehab Mustafa $u Department of Medical Physiology, College of Medicine, King Khalid University, Asir 61421, Saudi Arabia
700    1_
$a Son, Ninh The $u Institute of Chemistry, Vietnam Academy of Science and Technology (VAST), 18 Hoang Quoc Viet, Caugiay, Hanoi 10000, Viet Nam
700    1_
$a Ha, Nguyen Xuan $u Institute of Natural Products Chemistry, VAST, 18 Hoang Quoc Viet, Caugiay, Hanoi 10000, Viet Nam
700    1_
$a Hamissa, Mohamed Farouk $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences, Prague, Czech Republic
700    1_
$a Elsawi, Ahmed E $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, P.O. Box 33516, Egypt
700    1_
$a Elkaeed, Eslam B $u Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia. Electronic address: ekaeed@um.edu.sa
700    1_
$a Dziadek, Bozena $u Department of Molecular Microbiology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
700    1_
$a Eldehna, Wagdy M $u Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, P.O. Box 33516, Egypt. Electronic address: wagdy2000@gmail.com
700    1_
$a Dziadek, Jaroslaw $u Laboratory of Genetics and Physiology of Mycobacterium, Institute of Medical Biology of the Polish Academy of Sciences, Lodz, Poland. Electronic address: jdziadek@cbm.pan.pl
773    0_
$w MED00000771 $t Bioorganic chemistry $x 1090-2120 $g Roč. 144 (20240120), s. 107138
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38262087 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155547 $b ABA008
999    __
$a ok $b bmc $g 2081089 $s 1216671
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 144 $c - $d 107138 $e 20240120 $i 1090-2120 $m Bioorganic chemistry $n Bioorg Chem $x MED00000771
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options